Are nilotinib‐associated vascular adverse events an under‐estimated problem?. (11th March 2015)

• Record Type: Journal Article
• Authors: Stève‐Dumont, Marie; Baldin, Bernadette; Legros, Laurence; Thyss, Antoine; Re, Daniel; Rocher, Fanny; Ajmia, Florian; Spreux, Anne; Drici, Milou‐Daniel
• Is Part Of: Fundamental & clinical pharmacology. Volume 29:Number 2(2015)
• Page Start: 204
• Page End: 208
• Publication Date: 2015-03-11
• Subjects: arteriosclerosis -- chronic myeloid leukaemia -- lower extremity arterial disease -- nilotinib -- stenosis -- tyrosine kinase inhibitor; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/fcp.12102
• Languages: English
• ISSNs: 0767-3981

Abstract

Abstract: Vascular adverse events have been reported with nilotinib, a tyrosine kinase inhibitor prescribed for chronic myeloid leukaemia. However, few data specify their incidence, or whether they occur in predisposed patients. Hence, we prospectively studied 30 consecutive patients to assess the frequency of such adverse reactions and determine whether the patients presenting with these adverse events bear predisposing factors. From 3 to 73 months after nilotinib initiation, 10 of the 30 patients experienced vascular events. Three patients of these 10 were devoid of any patent cardiovascular risk factor, except for age. This study points out an occurrence more frequent than expected of vascular adverse events associated with nilotinib (> 30% vs. < 1% in summary of product characteristics), and particularly of vascular events of late onset in patients with no pre‐existing risk factors.